Avectas
Avectas is a cell engineering technology company dedicated to advancing the future of cell therapy. They have developed the Solupore platform, a non-viral delivery system that enables the manufacturing of healthier, more functional cells for patients. Their technology supports complex gene editing and challenging cargo delivery, aiming to improve patient outcomes and facilitate the development of next-generation cell therapies. The company actively collaborates with partners and researchers to expand the application of their innovative platform.
Industries
Nr. of Employees
small (1-50)
Avectas
Ground Floor Building 10, Cherrywood Business Park, Co.Dublin, D18 T3Y1
Patents
Payload delivery across cell membranes using continuous flow fluidic system
US-12104166-B2
View DetailsVector-free delivery of gene editing proteins and compositions to cells and tissues
US-11827899-B2
View Details
Payload delivery across cell membranes using continuous flow fluidic system
US-12104166-B2
View DetailsVector-free delivery of gene editing proteins and compositions to cells and tissues
US-11827899-B2
View DetailsProducts
Automated non-viral transfection platform for clinical cell therapy manufacturing
An automated, reproducible transfection platform designed for non-viral delivery of diverse cargos (RNA, DNA, protein) to primary immune cells and other cell types, engineered for integration into clinical GMP workflows and scalable manufacturing.
Automated non-viral transfection platform for clinical cell therapy manufacturing
An automated, reproducible transfection platform designed for non-viral delivery of diverse cargos (RNA, DNA, protein) to primary immune cells and other cell types, engineered for integration into clinical GMP workflows and scalable manufacturing.
Services
Collaborative R&D programs and early-access trials that enable partners (biotech, cell therapy developers, CDMOs, academic groups) to test and integrate non-viral transfection processes into development and manufacturing workflows.
Joint development projects with CDMOs to adapt non-viral delivery workflows for iPSC reprogramming, gene editing and generation of clinical-scale edited iPSC banks.
Collaborative R&D programs and early-access trials that enable partners (biotech, cell therapy developers, CDMOs, academic groups) to test and integrate non-viral transfection processes into development and manufacturing workflows.
Joint development projects with CDMOs to adapt non-viral delivery workflows for iPSC reprogramming, gene editing and generation of clinical-scale edited iPSC banks.
Expertise Areas
- Non-viral intracellular delivery for cell therapies
- Gene-editing delivery strategies (CRISPR RNP and HDR workflows)
- Clinical manufacturing integration and GMP-aligned process development
- iPSC reprogramming and edited iPSC bank generation
Key Technologies
- Reversible membrane permeabilization non-viral transfection
- mRNA delivery to primary cells
- RNP/CRISPR-Cas9 delivery
- Plasmid DNA delivery